Haematology

RyGen Biopharma develops biologic therapies targeting disorders related to blood cell production and platelet regulation. These therapies are designed to support patients with haematological conditions by improving platelet levels and maintaining healthy blood function.

Our development programs focus on advanced biologics that help manage conditions such as thrombocytopenia and other blood-related disorders. Through recombinant DNA technology and strong scientific expertise, RyGen aims to deliver safe, effective, and high-quality treatments aligned with global regulatory standards.